Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Read Jamie Madrigal, Dougald Monroe, Suzanne Sindi and Karin Leiderman’s Latest Analysis on Emicizumab
Jamie Madrigal, Dougald Monroe, Suzanne Sindi, Karin Leiderman/LinkedIn
Oct 4, 2025, 10:23

Read Jamie Madrigal, Dougald Monroe, Suzanne Sindi and Karin Leiderman’s Latest Analysis on Emicizumab

Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:

”Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions

This study used mathematical modeling and biochemical assays to dissect how emicizumab, a bispecific antibody bridging activated factor IXa and factor X, functions differently from factor VIII.

It revealed that high emicizumab levels inhibit factor X activation via tissue factor pathway due to reduced lipid surface binding but enhance factor IXa-dependent activation of factor X on lipid surfaces.

The model provides kinetic estimates and explains emicizumab’s mechanism of enhancing coagulation through lipid-surface interactions.

Read this paper.

Authors: Jamie Madrigal, Dougald Monroe, Suzanne Sindi, Karin Leiderman”

Read the full article in JTH.

Article: Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions

Authors: Jamie Madrigal, Dougald Monroe, Suzanne Sindi, Karin Leiderman

Read Jamie Madrigal, Dougald Monroe, Suzanne Sindi and Karin Leiderman's Latest Analysis on Emicizumab

Stay updated on all scientific advances with Hemostasis Today.

Bispecific Antibodies bleeding disorders Dougald Monroe Emicizumab FIX FX Health Hematology Hemostasis Hemostasis Today Jamie Madrigal Karin Leiderman lipid-surface reactions Medicine Suzanne Sindi thrombosis
NewsFeed